Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. García-Echeverría C, et al. Among authors: ruetz s. Cancer Cell. 2004 Mar;5(3):231-9. doi: 10.1016/s1535-6108(04)00051-0. Cancer Cell. 2004. PMID: 15050915 Free article.
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, Furet P, Gerspacher M, Lang M, Ledieu D, Nolan L, Ruetz S, Trappe J, Vangrevelinghe E, Wartmann M, Wyder L, Hofmann F, Radimerski T. Baffert F, et al. Among authors: ruetz s. Mol Cancer Ther. 2010 Jul;9(7):1945-55. doi: 10.1158/1535-7163.MCT-10-0053. Epub 2010 Jun 29. Mol Cancer Ther. 2010. PMID: 20587663
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Fabbro D, et al. Among authors: ruetz s. Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. doi: 10.1016/s0163-7258(02)00179-1. Pharmacol Ther. 2002. PMID: 12191602 Review.
beta-Homolysine oligomers: a new class of Trojan carriers.
García-Echeverría C, Ruetz S. García-Echeverría C, et al. Among authors: ruetz s. Bioorg Med Chem Lett. 2003 Jan 20;13(2):247-51. doi: 10.1016/s0960-894x(02)00885-5. Bioorg Med Chem Lett. 2003. PMID: 12482432
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, Holzer P, Masuya K, Würthner J, Halilovic E, Hofmann F, Sellers WR, Graus Porta D. Jeay S, et al. Among authors: ruetz s. Elife. 2015 May 12;4:e06498. doi: 10.7554/eLife.06498. Elife. 2015. PMID: 25965177 Free PMC article.
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, Chène P, Jeay S, Gessier F. Holzer P, et al. Among authors: ruetz s. J Med Chem. 2015 Aug 27;58(16):6348-58. doi: 10.1021/acs.jmedchem.5b00810. Epub 2015 Aug 5. J Med Chem. 2015. PMID: 26181851
42 results